Cholesterol

The cholesterol medication alirocumab, a PCSK9 inhibitor, combined with a statin appeared to reduce LDL cholesterol levels by more than 50% among patients after a heart transplant, according to a …

A cholesterol-lowering regimen that combines PCSK9 inhibitor alirocumab with statin therapy safely reduced low-density lipoprotein cholesterol (LDL-C) levels by more than 50% in adults early after heart transplantation, according to …